Listed

Protagonist Therapeutics, Inc

PTGXNasdaqCIK 1377121HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$213.5m, Q2 FY2026
Operating income$158.8m, Q2 FY2026
Net income$162.8m, Q2 FY2026
Protagonist Therapeutics, Inc, income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure60.0Revenue, Q4 FY2023, three months to 2023-12-31$60.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure255Revenue, Q1 FY2024, three months to 2024-03-31$255.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure4.2Revenue, Q2 FY2024, three months to 2024-06-30$4.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure4.7Revenue, Q3 FY2024, three months to 2024-09-30$4.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure171Revenue, Q4 FY2024, three months to 2024-12-31$170.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure28.3Revenue, Q1 FY2025, three months to 2025-03-31$28.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure5.5Revenue, Q2 FY2025, three months to 2025-06-30$5.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure4.7Revenue, Q3 FY2025, three months to 2025-09-30$4.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure7.4Revenue, Q4 FY2025, three months to 2025-12-31$7.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure56.4Revenue, Q1 FY2026, three months to 2026-03-31$56.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure213Revenue, Q2 FY2026, three months to 2026-06-30$213.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure
Research and development$m30.7Research and development, Q3 FY2023, three months to 2023-09-30$30.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure28.9Research and development, Q4 FY2023, three months to 2023-12-31$28.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure33.7Research and development, Q1 FY2024, three months to 2024-03-31$33.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure33.5Research and development, Q2 FY2024, three months to 2024-06-30$33.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure36.0Research and development, Q3 FY2024, three months to 2024-09-30$36.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure34.9Research and development, Q4 FY2024, three months to 2024-12-31$34.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure35.9Research and development, Q1 FY2025, three months to 2025-03-31$35.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure37.0Research and development, Q2 FY2025, three months to 2025-06-30$37.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure40.0Research and development, Q3 FY2025, three months to 2025-09-30$40.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure46.4Research and development, Q4 FY2025, three months to 2025-12-31$46.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure46.7Research and development, Q1 FY2026, three months to 2026-03-31$46.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure42.1Research and development, Q2 FY2026, three months to 2026-06-30$42.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure
Operating income$m(38.3)Operating income, Q3 FY2023, three months to 2023-09-30−$38.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure23.0Operating income, Q4 FY2023, three months to 2023-12-31$23.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure206Operating income, Q1 FY2024, three months to 2024-03-31$206.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure(38.8)Operating income, Q2 FY2024, three months to 2024-06-30−$38.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure(41.5)Operating income, Q3 FY2024, three months to 2024-09-30−$41.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure127Operating income, Q4 FY2024, three months to 2024-12-31$126.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure(19.3)Operating income, Q1 FY2025, three months to 2025-03-31−$19.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure(42.0)Operating income, Q2 FY2025, three months to 2025-06-30−$42.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure(46.4)Operating income, Q3 FY2025, three months to 2025-09-30−$46.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure(50.4)Operating income, Q4 FY2025, three months to 2025-12-31−$50.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure(3.6)Operating income, Q1 FY2026, three months to 2026-03-31−$3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure159Operating income, Q2 FY2026, three months to 2026-06-30$158.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2024-02-27, accession 0001558370-24-001850. Derived: 12-month figure less the 9-month figure.Report this figure3.3Income tax, Q1 FY2024, three months to 2024-03-31$3.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure(0.7)Income tax, Q2 FY2024, three months to 2024-06-30−$676.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure(0.4)Income tax, Q3 FY2024, three months to 2024-09-30−$420.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure2.0Income tax, Q4 FY2024, three months to 2024-12-31$2.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure0.2Income tax, Q2 FY2025, three months to 2025-06-30$172.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure0.7Income tax, Q4 FY2025, three months to 2025-12-31$666.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure(1.5)Income tax, Q1 FY2026, three months to 2026-03-31−$1.5m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure2.3Income tax, Q2 FY2026, three months to 2026-06-30$2.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure
Net income$m(34.1)Net income, Q3 FY2023, three months to 2023-09-30−$34.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure27.3Net income, Q4 FY2023, three months to 2023-12-31$27.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure207Net income, Q1 FY2024, three months to 2024-03-31$207.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure(30.6)Net income, Q2 FY2024, three months to 2024-06-30−$30.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure(33.2)Net income, Q3 FY2024, three months to 2024-09-30−$33.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure132Net income, Q4 FY2024, three months to 2024-12-31$131.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure(11.7)Net income, Q1 FY2025, three months to 2025-03-31−$11.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure(34.8)Net income, Q2 FY2025, three months to 2025-06-30−$34.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure(39.3)Net income, Q3 FY2025, three months to 2025-09-30−$39.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure(44.4)Net income, Q4 FY2025, three months to 2025-12-31−$44.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure3.8Net income, Q1 FY2026, three months to 2026-03-31$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure163Net income, Q2 FY2026, three months to 2026-06-30$162.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure
Diluted EPS$ per share(0.58)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figurenot reported3.26Diluted EPS, Q1 FY2024, three months to 2024-03-31$3.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure(0.50)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure(0.54)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figurenot reported(0.19)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure(0.55)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure(0.62)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figurenot reported0.05Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure2.29Diluted EPS, Q2 FY2026, three months to 2026-06-30$2.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure
Basic EPS$ per share(0.58)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.58 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figurenot reported3.41Basic EPS, Q1 FY2024, three months to 2024-03-31$3.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure(0.50)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure(0.54)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figurenot reported(0.19)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure(0.55)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure(0.62)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figurenot reported0.06Basic EPS, Q1 FY2026, three months to 2026-03-31$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure2.47Basic EPS, Q2 FY2026, three months to 2026-06-30$2.47 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure

Balance sheet

Cash and equivalents$420.1m, Q2 FY2026
Shareholders' equity$841.5m, Q2 FY2026
Protagonist Therapeutics, Inc, balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m231Cash and equivalents, Q3 FY2023, at 2023-09-30$230.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure187Cash and equivalents, FY2023, at 2023-12-31$186.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-25, accession 0001104659-26-019696.Report this figure173Cash and equivalents, Q1 FY2024, at 2024-03-31$172.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure356Cash and equivalents, Q2 FY2024, at 2024-06-30$355.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure131Cash and equivalents, Q3 FY2024, at 2024-09-30$131.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure97.2Cash and equivalents, FY2024, at 2024-12-31$97.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-25, accession 0001104659-26-019696.Report this figure140Cash and equivalents, Q1 FY2025, at 2025-03-31$139.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure169Cash and equivalents, Q2 FY2025, at 2025-06-30$168.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure114Cash and equivalents, Q3 FY2025, at 2025-09-30$113.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure128Cash and equivalents, FY2025, at 2025-12-31$128.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure194Cash and equivalents, Q1 FY2026, at 2026-03-31$193.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure420Cash and equivalents, Q2 FY2026, at 2026-06-30$420.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure
Current assets$m325Current assets, Q3 FY2023, at 2023-09-30$324.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-02, accession 0001558370-23-017460.Report this figure356Current assets, FY2023, at 2023-12-31$355.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-21, accession 0001558370-25-001317.Report this figure628Current assets, Q1 FY2024, at 2024-03-31$627.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-007081.Report this figure571Current assets, Q2 FY2024, at 2024-06-30$570.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0001558370-24-011095.Report this figure477Current assets, Q3 FY2024, at 2024-09-30$476.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure592Current assets, FY2024, at 2024-12-31$591.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-25, accession 0001104659-26-019696.Report this figure606Current assets, Q1 FY2025, at 2025-03-31$605.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure603Current assets, Q2 FY2025, at 2025-06-30$602.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure586Current assets, Q3 FY2025, at 2025-09-30$586.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure578Current assets, FY2025, at 2025-12-31$577.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure613Current assets, Q1 FY2026, at 2026-03-31$613.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure807Current assets, Q2 FY2026, at 2026-06-30$807.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure
Total assets$m330Total assets, Q3 FY2023, at 2023-09-30$330.0m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-02, accession 0001558370-23-017460.Report this figure358Total assets, FY2023, at 2023-12-31$358.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-21, accession 0001558370-25-001317.Report this figure629Total assets, Q1 FY2024, at 2024-03-31$629.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0001558370-24-007081.Report this figure615Total assets, Q2 FY2024, at 2024-06-30$614.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0001558370-24-011095.Report this figure604Total assets, Q3 FY2024, at 2024-09-30$603.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure745Total assets, FY2024, at 2024-12-31$744.7m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-25, accession 0001104659-26-019696.Report this figure742Total assets, Q1 FY2025, at 2025-03-31$742.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure718Total assets, Q2 FY2025, at 2025-06-30$718.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure702Total assets, Q3 FY2025, at 2025-09-30$701.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure668Total assets, FY2025, at 2025-12-31$668.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure697Total assets, Q1 FY2026, at 2026-03-31$697.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure886Total assets, Q2 FY2026, at 2026-06-30$885.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure
Current liabilities$m27.9Current liabilities, Q3 FY2023, at 2023-09-30$27.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-02, accession 0001558370-23-017460.Report this figure21.3Current liabilities, FY2023, at 2023-12-31$21.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-21, accession 0001558370-25-001317.Report this figure39.9Current liabilities, Q1 FY2024, at 2024-03-31$39.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-007081.Report this figure41.6Current liabilities, Q2 FY2024, at 2024-06-30$41.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0001558370-24-011095.Report this figure44.6Current liabilities, Q3 FY2024, at 2024-09-30$44.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure47.4Current liabilities, FY2024, at 2024-12-31$47.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-25, accession 0001104659-26-019696.Report this figure35.1Current liabilities, Q1 FY2025, at 2025-03-31$35.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure35.5Current liabilities, Q2 FY2025, at 2025-06-30$35.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure44.9Current liabilities, Q3 FY2025, at 2025-09-30$44.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure45.4Current liabilities, FY2025, at 2025-12-31$45.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure34.5Current liabilities, Q1 FY2026, at 2026-03-31$34.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure37.2Current liabilities, Q2 FY2026, at 2026-06-30$37.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure
Total liabilities$m27.9Total liabilities, Q3 FY2023, at 2023-09-30$27.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-02, accession 0001558370-23-017460.Report this figure21.3Total liabilities, FY2023, at 2023-12-31$21.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-21, accession 0001558370-25-001317.Report this figure68.8Total liabilities, Q1 FY2024, at 2024-03-31$68.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0001558370-24-007081.Report this figure73.3Total liabilities, Q2 FY2024, at 2024-06-30$73.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0001558370-24-011095.Report this figure71.9Total liabilities, Q3 FY2024, at 2024-09-30$71.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure69.4Total liabilities, FY2024, at 2024-12-31$69.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-25, accession 0001104659-26-019696.Report this figure53.1Total liabilities, Q1 FY2025, at 2025-03-31$53.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure50.0Total liabilities, Q2 FY2025, at 2025-06-30$50.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure56.3Total liabilities, Q3 FY2025, at 2025-09-30$56.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure53.5Total liabilities, FY2025, at 2025-12-31$53.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure42.0Total liabilities, Q1 FY2026, at 2026-03-31$42.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure44.0Total liabilities, Q2 FY2026, at 2026-06-30$44.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m302Shareholders' equity, Q3 FY2023, at 2023-09-30$302.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure337Shareholders' equity, FY2023, at 2023-12-31$336.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-25, accession 0001104659-26-019696.Report this figure560Shareholders' equity, Q1 FY2024, at 2024-03-31$560.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure541Shareholders' equity, Q2 FY2024, at 2024-06-30$541.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure532Shareholders' equity, Q3 FY2024, at 2024-09-30$531.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure675Shareholders' equity, FY2024, at 2024-12-31$675.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure689Shareholders' equity, Q1 FY2025, at 2025-03-31$689.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure668Shareholders' equity, Q2 FY2025, at 2025-06-30$668.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure645Shareholders' equity, Q3 FY2025, at 2025-09-30$645.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure615Shareholders' equity, FY2025, at 2025-12-31$614.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure655Shareholders' equity, Q1 FY2026, at 2026-03-31$655.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure842Shareholders' equity, Q2 FY2026, at 2026-06-30$841.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure

Cash flow

Operating cash flow$219.1m, Q2 FY2026
Capital expenditure$168.0k, Q2 FY2026
Protagonist Therapeutics, Inc, cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(26.6)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$26.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0001558370-24-014888. Derived: 9-month figure less the 6-month figure.Report this figure17.0Operating cash flow, Q4 FY2023, three months to 2023-12-31$17.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure(27.4)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$27.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure269Operating cash flow, Q2 FY2024, three months to 2024-06-30$268.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-06, accession 0001558370-25-010534. Derived: 6-month figure less the 3-month figure.Report this figure(27.9)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$27.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107816. Derived: 9-month figure less the 6-month figure.Report this figure(29.2)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$29.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure125Operating cash flow, Q1 FY2025, three months to 2025-03-31$125.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure(28.8)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$28.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001104659-26-091123. Derived: 6-month figure less the 3-month figure.Report this figure(1.9)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107816. Derived: 9-month figure less the 6-month figure.Report this figure(37.0)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$37.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure(48.9)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$48.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure219Operating cash flow, Q2 FY2026, three months to 2026-06-30$219.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001104659-26-091123. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.4Capital expenditure, Q3 FY2023, three months to 2023-09-30$404.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-07, accession 0001558370-24-014888. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$19.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$242.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$28.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-06, accession 0001558370-25-010534. Derived: 6-month figure less the 3-month figure.Report this figure0.8Capital expenditure, Q3 FY2024, three months to 2024-09-30$775.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107816. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2024, three months to 2024-12-31$310.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure0.5Capital expenditure, Q1 FY2025, three months to 2025-03-31$545.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure0.8Capital expenditure, Q2 FY2025, three months to 2025-06-30$813.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001104659-26-091123. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$88.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107816. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$144.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001104659-26-019696. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2026, three months to 2026-03-31$215.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure0.2Capital expenditure, Q2 FY2026, three months to 2026-06-30$168.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001104659-26-091123. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)71.01m, Q2 FY2026
Protagonist Therapeutics, Inc, shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares49.1Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3049,107,639 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-02, accession 0001558370-23-017460.Report this figure50.6Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3150,573,650 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0001558370-24-007081.Report this figure56.8Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3056,775,742 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0001558370-24-011095.Report this figure59.2Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3059,182,899 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0001558370-24-014888.Report this figure63.6Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3163,595,328 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-06, accession 0001558370-25-006530.Report this figure61.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3061,305,289 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-06, accession 0001558370-25-010534.Report this figure61.8Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3061,767,934 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure63.0Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3162,963,806 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure63.5Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3063,510,537 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure63.8Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3063,772,332 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001104659-25-107816.Report this figure70.5Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3170,492,618 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001104659-26-055661.Report this figure71.0Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3071,007,011 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure

Shares outstanding: 64.71mShares outstanding, period not labelled, at 2026-07-3164,708,285 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-05, accession 0001104659-26-091123.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.